Figitumumab (Anti-IGF1R / CD221)

Figitumumab (Anti-IGF1R / CD221) is a human monoclonal antibody directed against the insulin-like growth factor type I receptor (IGF1R) with potential antineoplastic activity. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM. MW: 146.0 KD.
Supplier Selleck Chemicals
Product # A2942
Sku # A2942-1mg
Pricing 1mg, $370.00
Feedback